Home

KEYNOTE 042 pdf

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non

(PDF) Pembrolizumab versus chemotherapy for previously

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 tria PDF | On Apr 1, 2019, T S K Mok and others published 102OFinal analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy.

KEYNOTE-042 Open-Label-Phase-III-Studie. Therapienaive Patienten (n = 1.274) mit lokal fortgeschrittenem oder metastasiertem NSCLC, ohne EGFR- oder ALK-Alterationen, wurden 1 : 1 in den Erhalt von Pembrolizumab vs. Chemotherapie (Carboplatin + Paclitaxel oder Carboplatin + Pemetrexed) randomisiert. Primärer Studienendpunkt war das Gesamtüberleben (OS) in Patienten mit TPS ≥ 50 %, ≥ 20 %. 542 - Final Analysis of the Phase 3 KEYNOTE-042 Study: Pembrolizumab (Pembro) Versus Platinum-Based Chemotherapy (Chemo) as First-Line Therapy for Patients (Pts) With PD-L1-Positive Locally Advanced/Metastatic NSCLC. Date 11 Apr 2019. Session ESMO-IASLC Best Abstracts. Presenters Tony S.K. Mok. Citation. Annals of Oncology (2019) 30 (suppl_2): ii38-ii68. 10.1093/annonc/mdz063. Authors T.S.K. der Studien KEYNOTE 024 und KEYNOTE 042 durch. Dabei zeigt sich eine signifikante Verlängerung der Gesamtüberlebenszeit der Immunchemotherapie versus der Pembrolizumab Monotherapie mit ei-nem Hazard Ratio von 0,40. In einer präspezifizierten Subgruppenanalyse wird die Wirksamkeit von Pembrolizumab in Abhängigkeit vom eingesetzten Platinderivat untersucht. Hier zeigt sich ein größerer. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

In the KEYNOTE-042 regions there was less availability of and access to therapy, particularly immunotherapy, which is reflected in the lower percentage of patients in the chemotherapy group who received subsequent immunotherapy (20% vs 64% in KEYNOTE-024), although crossover to pembrolizumab was permitted during KEYNOTE-024. Progression-free survival, the primary endpoint of KEYNOTE-024, is. In KEYNOTE-042, we compared pembro with chemo at the lower TPS of ≥1% (NCT02220894). Methods: Eligible patients (pts) were randomized 1:1 to ≤35 cycles of pembro 200 mg Q3W or investigator's choice of ≤6 cycles of paclitaxel + carboplatin or pemetrexed (peme) + carboplatin with optional peme maintenance (nonsquamous only). Randomization was stratified by region (east Asia vs non-east.

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus

Request PDF | On Mar 1, 2021, B.C. Cho and others published FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC. KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49% Daniel Morgensztern Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA Correspondence to: Daniel Morgensztern. Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA. Email: danielmorgensztern@wustl.edu. KEYNOTE-189 trial is provided in the Supplementary Appendix, available at NEJM.org. This article was published on April 16, 2018, at NEJM.org. N Engl J Med 2018;378:2078-92. DOI: 10.1056/NEJMoa180100 Keynote 42 also confirms the results of Keynote 24 with superior efficacy and less toxicity for pembrolizumab compared to chemotherapy for NSCLC with TPS ≥50%. However, the results for Keynote 42 should be viewed with caution for tumors with TPS 1-49% as the superiority of pembrolizumab compared to chemotherapy for all patients with PD-L1 TPS ≥1% was likely driven by the subset of.

Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1-positive advanced non-small cell lung cancer (NSCLC). Tony Mok. x. Tony Mok. Search for articles by this author, Yi-Long Wu. x. Yi-Long Wu. Search for articles by this author, Patricia A, Watson. x. Patricia A, Watson. Search for articles by this author, Jin. KEYNOTE-042 is an international, randomized, open-label Phase 3 study (ClinicalTrials.gov, NCT02220894) investigating KEYTRUDA monotherapy compared to standard of care platinum-based chemotherapy in patients with locally advanced or metastatic PD-L1 positive (TPS ≥ 1%) NSCLC. Patients had no EGFR or ALK genomic tumor aberrations and had not previously received systemic therapy for advanced.

We pooled data for patients with previously treated or untreated PD-L1‒positive (tumor proportion score [TPS], ≥1%) advanced or metastatic NSCLC in KEYNOTE-001 (NCT01295827), KEYNOTE-010 (NCT01905657), KEYNOTE-024 (NCT02142738), and KEYNOTE-042 (NCT02220894). Patients received pembrolizumab (2 mg/kg, 10 mg/kg, or 200 mg every 3 wk or 10 mg/kg every 2 wk); chemotherapy was a comparator in. In the global KEYNOTE-042 study (Clinicaltrials.gov, NCT02220894), pembrolizumab significantly improved overall survival (OS) vs chemotherapy in patients with previously untreated programmed death ligand 1 (PD-L1)-positive locally advanced/metastatic non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations.We present results from patients in KEYNOTE-042 enrolled from China in the. KEYNOTE-042. KEYNOTE-042 compared pembrolizumab to histology dependent platinum-based doublets as initial treatment in locally advanced or metastatic patients with PD-L1 ≥1% on TCs and lacking EGFR activating mutations/ALK fusions. The trial headline was that pembrolizumab monotherapy might be an additional effective option for this patient population () Study participants had no targetable alterations and a PD-L1 TPS greater than or equal to 50% in KEYNOTE-024, but in KEYNOTE-042 (ClinicalTrials.gov Identifier: NCT02220894), authors evaluated the.

View PDF; Download full issue; Lung Cancer. Volume 135, September 2019, Pages 188-195. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Author links open overlay panel Kaname Nosaki a 1 Hideo Saka b Yukio Hosomi c Paul Baas d Gilberto de. In the global KEYNOTE‐042 study (Clinicaltrials.gov, NCT02220894), pembrolizumab significantly improved overall survival (OS) vs chemotherapy in patients with previously untreated programmed death ligand 1 (PD‐L1)‐positive locally advanced/metastatic non-small‐cell lung cancer (NSCLC) without EGFR/ALK alterations.We present results from patients in KEYNOTE‐042 enrolled from China. Background: Novel second-line treatments are needed for patients with advanced urothelial cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a superior overall survival (OS) benefit of pembrolizumab, a programmed death 1 inhibitor, versus chemotherapy in patients with advanced UC that progressed on platinum-based chemotherapy

KEYNOTE-042 and the role for single agent pembrolizumab in

currently under EMA review, based on the result of KEYNOTE-042 study (EMEA/H/C/003820/II/0057 procedure). Most individual trials and meta-analyses evaluating chemotherapy options in the firstline treatment of - advanced NSCLC did not report any differential efficacy in patients with squamous NCSLC. Therefore, platinum-based (cisplatin/carboplatin) doublets with the addition of a third. KEYNOTE 407 und KEYNOTE 042 an, Patientinnen und Patienten, die vom Kontrollarm auf eine Monotherapie mit Pembrolizumab wechseln, in den statistischen Analysen zum te Zeitpunkt des Therapiewechsels zu zensieren. Eine solche Analyse wäre nicht sinnvoll zu interpretieren. Diese Angaben macht er in Modul 4 B [2] zum nicht plattenepithelialen NSCLC nicht, beschreibt jedoch auch nicht, dass keine.

Pembrolizumab versus chemotherapy for previously untreated

Randomized Clinical Trial of Pembrolizumab Versus

  1. (PDF) Pembrolizumab versus chemotherapy for previously
  2. Pembrolizumab versus chemotherapy for previously untreated
  3. (PDF) 102OFinal analysis of the phase III KEYNOTE-042
  4. KEYNOTE-042: Pembrolizumab First Line bei NSCLC mit PD-L1
  5. Final Analysis of the Phase 3 KEYNOTE-042 Study
  6. Study of Pembrolizumab (MK-3475) Versus Platinum-Based
  7. Pembrolizumab (pembro) versus platinum-based chemotherapy

FP13.04 KEYNOTE-042 3-Year Survival Update: 1L ..

  1. 1965 Editorial Commentary KEYNOTE-042 and the role for
  2. Pembrolizumab plus Chemotherapy in Metastatic Non-Small
  3. Keynote 42: Pembrolizumab, PD-L1, and where to draw the lin
  4. Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475
  5. Outcomes With Pembrolizumab Monotherapy in Patients With
  6. Randomized clinical trial of - Wiley Online Librar

KEYNOTE-042: is lowering the PD-L1 threshold for first

  1. KEYNOTE-042: Pembrolizumab Improved Overall Survival in
  2. Safety and efficacy of pembrolizumab monotherapy in
  3. Randomized clinical trial of pembrolizumab vs chemotherapy
  4. Randomized phase III KEYNOTE-045 trial of pembrolizumab
  5. Frontline PD-L1 Monotherapy: KEYNOTE-042 and IMpower110
  6. How to make clickable pdf in Keynote
高齢者肺がんの治療 | 健康長寿ネットKEYNOTE for NSCLC - westsaitamaresp ページ!Pembrolizumab (Keytruda®) as first-line therapy for PD-L1